{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:51:10Z","timestamp":1776433870770,"version":"3.51.2"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221653","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T17:37:51Z","timestamp":1567791471000},"page":"e0221653","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir\/ritonavir-based therapy: Substudy of a randomized trial"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-2875","authenticated-orcid":true,"given":"Darrell H. S.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Rolon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ines","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Sued","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet M.","family":"Raboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Szadkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Argentinean GARDEL research network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"issue":"4","key":"pone.0221653.ref001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"HF Gunthard","year":"2014","journal-title":"JAMA"},{"key":"pone.0221653.ref002","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2016 March 22]. Available from: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf."},{"issue":"2","key":"pone.0221653.ref003","doi-asserted-by":"crossref","first-page":"e0148231","DOI":"10.1371\/journal.pone.0148231","article-title":"Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients","volume":"11","author":"JG Baril","year":"2016","journal-title":"PLoS One"},{"key":"pone.0221653.ref004","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.2147\/DDDT.S140767","article-title":"Two-drug regimens for treatment of naive HIV-1 infection and as maintenance therapy","volume":"12","author":"KC Corado","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"pone.0221653.ref005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","article-title":"Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial","volume":"14","author":"P Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"pone.0221653.ref006","unstructured":"Cahn P, editor Durability of Dual Therapy (DT) with Lopinavir\/Ritonavir (LPV\/r) and Lamivudine (3TC) in Comparison to Standard Triple Drug Therapy (TT): 96-week Results of the GARDEL Study. 15th European AIDS Conference Abstract 961; 2015; Barcelona, Spain."},{"issue":"4","key":"pone.0221653.ref007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"NI Wada","year":"2015","journal-title":"AIDS"},{"issue":"2","key":"pone.0221653.ref008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/QAD.0000000000000815","article-title":"Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia","volume":"30","author":"A Guihot","year":"2016","journal-title":"AIDS"},{"issue":"4","key":"pone.0221653.ref009","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","article-title":"Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s","volume":"61","author":"T Kelesidis","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0221653.ref010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-291X(88)81056-8","article-title":"The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes","volume":"155","author":"HJ Moshage","year":"1988","journal-title":"Biochemical and biophysical research communications"},{"issue":"25","key":"pone.0221653.ref011","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"JK Pai","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0221653.ref012","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"PM Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0221653.ref013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archinte.166.1.64","article-title":"C-reactive protein is a marker for human immunodeficiency virus disease progression","volume":"166","author":"B Lau","year":"2006","journal-title":"Arch Intern Med"},{"issue":"10","key":"pone.0221653.ref014","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"LH Kuller","year":"2008","journal-title":"PLoS Med"},{"issue":"3","key":"pone.0221653.ref015","doi-asserted-by":"crossref","first-page":"e24243","DOI":"10.1371\/journal.pone.0024243","article-title":"Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease","volume":"7","author":"L Ledwaba","year":"2012","journal-title":"PLoS One"},{"key":"pone.0221653.ref016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12879-016-1567-2","article-title":"HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection","volume":"16","author":"FM Lamoury","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"2","key":"pone.0221653.ref017","doi-asserted-by":"crossref","first-page":"e0149143","DOI":"10.1371\/journal.pone.0149143","article-title":"Non-Classical Monocytes and Monocyte Chemoattractant Protein-1 (MCP-1) Correlate with Coronary Artery Calcium Progression in Chronically HIV-1 Infected Adults on Stable Antiretroviral Therapy","volume":"11","author":"N Zungsontiporn","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"pone.0221653.ref018","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1212\/01.WNL.0000145763.68284.15","article-title":"Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia","volume":"63","author":"JJ Sevigny","year":"2004","journal-title":"Neurology"},{"key":"pone.0221653.ref019","doi-asserted-by":"crossref","first-page":"484378","DOI":"10.1155\/2013\/484378","article-title":"TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?","volume":"2013","author":"A Kumar","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"1","key":"pone.0221653.ref020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"KY Liang","year":"1986","journal-title":"Biometrika"},{"key":"pone.0221653.ref021","volume-title":"Analysis of Longitudinal Data","author":"PJ Diggle","year":"1994"},{"issue":"3","key":"pone.0221653.ref022","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/QAI.0b013e3181e66216","article-title":"Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort","volume":"55","author":"PC Tien","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"pone.0221653.ref023","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/infdis\/jir134","article-title":"Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death","volume":"203","author":"DR Boulware","year":"2011","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0221653.ref024","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"PW Hunt","year":"2014","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0221653.ref025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"AR Tenorio","year":"2014","journal-title":"J Infect Dis"},{"issue":"9","key":"pone.0221653.ref026","doi-asserted-by":"crossref","first-page":"e45716","DOI":"10.1371\/journal.pone.0045716","article-title":"Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study","volume":"7","author":"SK Gupta","year":"2012","journal-title":"PLoS One"},{"key":"pone.0221653.ref027","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2334-14-122","article-title":"Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study","volume":"14","author":"S Hattab","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"8","key":"pone.0221653.ref028","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/jac\/dkt120","article-title":"Associations of T cell activation and inflammatory biomarkers with virological response to darunavir\/ritonavir plus raltegravir therapy","volume":"68","author":"B Taiwo","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0221653.ref029","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/infdis\/jiv004","article-title":"Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals","volume":"212","author":"CO Hileman","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0221653.ref030","doi-asserted-by":"crossref","first-page":"e33948","DOI":"10.1371\/journal.pone.0033948","article-title":"Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection","volume":"7","author":"J Ananworanich","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"pone.0221653.ref031","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/09680519050110040701","article-title":"Modulatory effects of sCD14 and LBP on LPS-host cell interactions","volume":"11","author":"RL Kitchens","year":"2005","journal-title":"J Endotoxin Res"},{"issue":"6","key":"pone.0221653.ref032","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection","volume":"203","author":"NG Sandler","year":"2011","journal-title":"J Infect Dis"},{"issue":"7","key":"pone.0221653.ref033","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/cid\/cir989","article-title":"Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV?","volume":"54","author":"AC Justice","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0221653.ref034","doi-asserted-by":"crossref","first-page":"e55038","DOI":"10.1371\/journal.pone.0055038","article-title":"Kinetics of microbial translocation markers in patients on efavirenz or lopinavir\/r based antiretroviral therapy","volume":"8","author":"J Vesterbacka","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"pone.0221653.ref035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/157016212803306032","article-title":"Immune reconstitution in HIV+ subjects on lopinavir\/ritonavir-based HAART according to the severity of pre-therapy CD4+","volume":"10","author":"G Marchetti","year":"2012","journal-title":"Curr HIV Res"},{"key":"pone.0221653.ref036","doi-asserted-by":"crossref","first-page":"19246","DOI":"10.7448\/IAS.17.1.19246","article-title":"Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation","volume":"17","author":"B Torres","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0221653.ref037","article-title":"Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study","volume":"17","author":"P Cahn","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0221653.ref038","article-title":"Simplification to atazanavir\/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial","volume":"17","author":"M Fabbiani","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"pone.0221653.ref039","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/jac\/dky125","article-title":"Systemic inflammation markers after simplification to atazanavir\/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy","volume":"73","author":"S Belmonti","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"pone.0221653.ref040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"JA Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0221653.ref041","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"P Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"10167","key":"pone.0221653.ref042","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"P Cahn","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"pone.0221653.ref043","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"V Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"10123","key":"pone.0221653.ref044","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"JM Llibre","year":"2018","journal-title":"Lancet"},{"key":"pone.0221653.ref045","unstructured":"Orkin C, Arest\u00e9h K, G\u00f3rgolas Hern\u00e1ndez-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. Conference on Retroviruses and Opportunistic Infections; March 4\u20137, 2019; Seattle, WA. Abstract 140.2019."},{"issue":"2","key":"pone.0221653.ref046","article-title":"Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy","volume":"2","author":"DHS Tan","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"pone.0221653.ref047","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.02.012","article-title":"Glucose Metabolism in T Cells and Monocytes: New Perspectives in HIV Pathogenesis","volume":"6","author":"CS Palmer","year":"2016","journal-title":"EBioMedicine"},{"key":"pone.0221653.ref048","unstructured":"Krishnan AK, Bosch RJ, Rodriguez B, Hunt PW, Wilson C, Deeks SG, et al. Correlates of Inflammatory Markers After One Year of Suppressive Antiretroviral Treatment (ART). Conference on Retroviruses and Opportunistic Infections Abstract 757; Boston, MA2014."},{"issue":"12","key":"pone.0221653.ref049","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"KY Smith","year":"2009","journal-title":"Aids"},{"issue":"11","key":"pone.0221653.ref050","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/QAD.0b013e328354f4fb","article-title":"Inflammation markers after randomization to abacavir\/lamivudine or tenofovir\/emtricitabine with efavirenz or atazanavir\/ritonavir","volume":"26","author":"GA McComsey","year":"2012","journal-title":"AIDS (London, England)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:07:41Z","timestamp":1588993661000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221653"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221653","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]}}}